Sahra Ali

40PUBLICATIONS
113CO-AUTHORS
Molecular targetsRegenerative medicine (incl. stem cells)Gene and molecular therapyRespiratory diseasesEpidemiological modelling
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (40)

|Jul 09, 2026
Integrating novel therapeutic strategies in myeloproliferative neoplasms: Driving disease-directed progress.

|Jun 02, 2026
Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor-Naïve Myelofibrosis: Phase III SENTRY Trial.

|Apr 01, 2026
Combination treatments for myelofibrosis in JAK inhibitor-naive patients: evidence, rationale, and clinical direction.

Laura Li Gagnon, Claire N Harrison

|Mar 27, 2026
Ruxolitinib treatment in patients with polycythemia vera reduces JAK2 variant allele frequency and improves symptom burden and hematocrit control.

Claire N Harrison, Jean-Jacques Kiladjian, J E Hamer-Maansson

|Nov 24, 2025
European LeukemiaNet criteria for safety and efficacy evaluation of new drugs for myelofibrosis.

Monia Marchetti, Alessandro Maria Vannucchi, John O Mascarenhas

|Aug 27, 2025
Mesenchymal stromal cells from JAK2 V617F myeloproliferative neoplasms support healthy and malignant hematopoiesis in a humanized scaffold model in vivo.

Alessandra Ferrelli, Syed Mian, Marion Piganeau

Pageof 7

Frequent Collaborators

11 joint publications

Donal P McLornan

7 joint publications

Adam Mead

6 joint publications

Natalia Curto-Garcia

5 joint publications

Ruben Mesa